OBJECTIVE: The objective of our study was to predict response to chemoradiation therapy in patients with head and neck squamous cell carcinoma (HNSCC) by combined use of diffusion-weighted imaging (DWI) and high-spatial-resolution, high-temporal-resolution dynamic contrast-enhanced MRI (DCE-MRI) parameters from primary tumors and metastatic nodes. SUBJECTS AND METHODS: Thirty-two patients underwent pretreatment DWI and DCE-MRI using a modified radial imaging sequence. Postprocessing of data included motion-correction algorithms to reduce motion artifacts. The median apparent diffusion coefficient (ADC), volume transfer constant (K(trans)), extracellular extravascular volume fraction (v(e)), and plasma volume fraction (v(p)) were computed from primary tumors and nodal masses. The quality of the DCE-MRI maps was estimated using a threshold median chi-square value of 0.10 or less. Multivariate logistic regression and receiver operating characteristic curve analyses were used to determine the best model to discriminate responders from nonresponders. RESULTS: Acceptable χ(2) values were observed from 84% of primary tumors and 100% of nodal masses. Five patients with unsatisfactory DCE-MRI data were excluded and DCE-MRI data for three patients who died of unrelated causes were censored from analysis. The median follow-up for the remaining patients (n = 24) was 23.72 months. When ADC and DCE-MRI parameters (K(trans), v(e), v(p)) from both primary tumors and nodal masses were incorporated into multivariate logistic regression analyses, a considerably higher discriminative accuracy (area under the curve [AUC] = 0.85) with a sensitivity of 81.3% and specificity of 75% was observed in differentiating responders (n = 16) from nonresponders (n = 8). CONCLUSION: The combined use of DWI and DCE-MRI parameters from both primary tumors and nodal masses may aid in prediction of response to chemoradiation therapy in patients with HNSCC.
OBJECTIVE: The objective of our study was to predict response to chemoradiation therapy in patients with head and neck squamous cell carcinoma (HNSCC) by combined use of diffusion-weighted imaging (DWI) and high-spatial-resolution, high-temporal-resolution dynamic contrast-enhanced MRI (DCE-MRI) parameters from primary tumors and metastatic nodes. SUBJECTS AND METHODS: Thirty-two patients underwent pretreatment DWI and DCE-MRI using a modified radial imaging sequence. Postprocessing of data included motion-correction algorithms to reduce motion artifacts. The median apparent diffusion coefficient (ADC), volume transfer constant (K(trans)), extracellular extravascular volume fraction (v(e)), and plasma volume fraction (v(p)) were computed from primary tumors and nodal masses. The quality of the DCE-MRI maps was estimated using a threshold median chi-square value of 0.10 or less. Multivariate logistic regression and receiver operating characteristic curve analyses were used to determine the best model to discriminate responders from nonresponders. RESULTS: Acceptable χ(2) values were observed from 84% of primary tumors and 100% of nodal masses. Five patients with unsatisfactory DCE-MRI data were excluded and DCE-MRI data for three patients who died of unrelated causes were censored from analysis. The median follow-up for the remaining patients (n = 24) was 23.72 months. When ADC and DCE-MRI parameters (K(trans), v(e), v(p)) from both primary tumors and nodal masses were incorporated into multivariate logistic regression analyses, a considerably higher discriminative accuracy (area under the curve [AUC] = 0.85) with a sensitivity of 81.3% and specificity of 75% was observed in differentiating responders (n = 16) from nonresponders (n = 8). CONCLUSION: The combined use of DWI and DCE-MRI parameters from both primary tumors and nodal masses may aid in prediction of response to chemoradiation therapy in patients with HNSCC.
Authors: C R Habermann; P Gossrau; H Kooijman; J Graessner; M C Cramer; M G Kaul; F Reitmeier; M Jaehne; G Adam Journal: AJNR Am J Neuroradiol Date: 2007-09 Impact factor: 3.825
Authors: R A Cooper; B M Carrington; J A Loncaster; S M Todd; S E Davidson; J P Logue; A D Luthra; A P Jones; I Stratford; R D Hunter; C M West Journal: Radiother Oncol Date: 2000-10 Impact factor: 6.280
Authors: P M Specenier; D Van den Weyngaert; C Van Laer; J Weyler; J Van den Brande; M T Huizing; J Dyck; D Schrijvers; J B Vermorken Journal: Ann Oncol Date: 2007-09-06 Impact factor: 32.976
Authors: A David McCollum; Steven C Burrell; Robert I Haddad; Charles M Norris; Roy B Tishler; Mary Ann Case; Marshall R Posner; Annick D Van den Abbeele Journal: Head Neck Date: 2004-10 Impact factor: 3.147
Authors: Jacobus Fa Jansen; Yonggang Lu; Gaorav Gupta; Nancy Y Lee; Hilda E Stambuk; Yousef Mazaheri; Joseph O Deasy; Amita Shukla-Dave Journal: World J Radiol Date: 2016-01-28
Authors: C S Schouten; P de Graaf; E Bloemena; B I Witte; B J M Braakhuis; R H Brakenhoff; C R Leemans; J A Castelijns; R de Bree Journal: AJNR Am J Neuroradiol Date: 2015-02-26 Impact factor: 3.825
Authors: Kee H Wong; Rafal Panek; Shreerang A Bhide; Christopher M Nutting; Kevin J Harrington; Katie L Newbold Journal: Br J Radiol Date: 2017-03 Impact factor: 3.039
Authors: Thomas Hauser; Marco Essig; Alexandra Jensen; Lars Gerigk; Frederik Bernd Laun; Marc Münter; Dirk Simon; Bram Stieltjes Journal: Neuroradiology Date: 2013-02-17 Impact factor: 2.804
Authors: Marcelo A Queiroz; Martin Hüllner; Felix Kuhn; Gerhardt Huber; Christian Meerwein; Spyros Kollias; Gustav von Schulthess; Patrick Veit-Haibach Journal: Eur J Nucl Med Mol Imaging Date: 2014-08-05 Impact factor: 9.236
Authors: M Ravanelli; A Grammatica; M Maddalo; M Ramanzin; G M Agazzi; E Tononcelli; S Battocchio; P Bossi; M Vezzoli; R Maroldi; D Farina Journal: AJNR Am J Neuroradiol Date: 2020-07-30 Impact factor: 3.825
Authors: Marcelo A Queiroz; Martin Hüllner; Felix Kuhn; Gerhardt Huber; Christian Meerwein; Spyros Kollias; Gustav von Schulthess; Patrick Veit-Haibach Journal: Eur J Nucl Med Mol Imaging Date: 2014-02-28 Impact factor: 9.236